Scholars@Duke
April Kelly Scott Salama

April Kelly Scott Salama

Associate Professor of Medicine
Medicine, Medical Oncology
DUMC 3198, Durham, NC 27710
30 Duke Medicine Circle, 25177 Morris Bldg, Durham, NC 27710

Scholarly Works - Conferences

Abstract CT029: Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial

Conference Cancer Research · April 17, 2026 AbstractBackground:Metastatic uveal melanoma (mUM) has a very poor prognosis with a historical survival rate of <10% at ... Full text Cite

Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H.

Conference Journal of Clinical Oncology · June 1, 2024 3110Background: The NCI-MATCH precision medicine trial assigns patients (pts) with solid tumors, lymphomas or multiple myeloma to a targeted therapy based on genetic alterations identified in pretreatment biopsies. Arm H (EAY131-H) evaluated the combinatio ... Full text Cite

Intracranial Control with Combined Dual ImmuneCheckpoint Blockade and SRS for Melanoma and NSCLC Brain Metastases

Conference INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS · October 1, 2023 Link to item Cite

Clinical Outcomes Following an Initial Stereotactic Radiosurgery Course for Brain Metastases from Melanoma

Conference INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS · October 1, 2023 Link to item Cite

Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).

Conference Journal of Clinical Oncology · June 1, 2023 9511 Background: Standard MAPK-targeted therapy (tx) for pts with BRAF MT MM involves combined BRAF and MEK inhibition with high efficacy in advanced melanoma, but durability of response is limited by acquired resistance. One com ... Full text Cite

Patterns of care delivery and outcomes in patients with melanoma brain metastases treated with ipilimumab/nivolumab.

Conference Journal of Clinical Oncology · June 1, 2023 e21510 Background: Patients (Pts) with metastatic melanoma presenting with brain metastases (MBM) have a high morbidity and mortality risk. The combination of ipilimumab/nivolumab (I/N) has demonstrated high intracranial response ... Full text Cite

In-transit Melanoma: A Multi-institutional Analysis of Outcomes

Conference ANNALS OF SURGICAL ONCOLOGY · May 2022 Link to item Cite

An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM).

Conference Journal of Clinical Oncology · May 20, 2021 9521 Background: Previous work has shown that MBM have a unique molecular profile compared to ECM. Description of the biology of MBM will facilitate the design of rational therapies for patients (pts) with MBM. Methods: We analyz ... Full text Cite

Cutaneous melanoma: Management of melanoma brain metastases and molecular testing

Conference Jnccn Journal of the National Comprehensive Cancer Network · May 1, 2021 Several advances in diagnosis and treatment of cutaneous melanoma were discussed at the NCCN 2021 Virtual Annual Conference. First, advances in immunotherapies and targeted agents have enhanced the role of systemic therapies in the up-front management of b ... Full text Cite

Mind the Gap: Gendered Publication Trends in Academic Oncology

Conference International Journal of Radiation Oncology*Biology*Physics · September 2019 Full text Cite

Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.

Conference Journal of Clinical Oncology · May 20, 2019 3002 Background: The NCI-MATCH precision medicine trial assigns patients (pts) with solid tumors, lymphomas, or multiple myeloma with progression on prior treatment to a targeted therapy based on genetic alterations identified in ... Full text Cite

Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases

Conference Blood · November 29, 2018 AbstractIntroduction: The development of immune checkpoint inhibitors (ICPis) has ushered in a new paradigm for the treatment of both solid and liquid malignancies. However, these therapies, which promote an ... Full text Cite

Cemiplimab (REGN2810): A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study.

Conference Journal of Clinical Oncology · February 10, 2018 195 Background: There is no established standard of care for unresectable locally advanced or metastatic CSCC. UV-induced DNA damage causes hypermutation in most CSCCs. Therefore, these tumors may be responsive to PD-1 checkpoint ... Full text Cite

A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.

Conference Journal of Clinical Oncology · May 20, 2017 109 Background: gpNMB is an internalizable transmembrane glycoprotein expressed in melanoma and multiple other tumor types. The ADC GV (CDX-011) delivers the potent cytotoxin MMAE to gpNMB+ cells. GV has shown promising activity ... Full text Cite

Radiosurgery for Brain Metastases in Melanoma Patients Receiving Ipilimumab

Conference International Journal of Radiation Oncology*Biology*Physics · November 2015 Full text Cite